Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Double-blind, Placebo-controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 3802876 in Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)

NCT07325526 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT07325526
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07325526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Double-blind, Placebo-controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 3802876 in Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Recruiting
Start date
February 27, 2026
Completion date
August 5, 2027
Enrollment
30 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

liver cirrhosis